BioCentury
ARTICLE | Clinical News

RhIGF-1: Phase III data

June 21, 2004 7:00 AM UTC

Interim results from an open-label U.S. Phase III trial in 65 children showed that in 54 patients that received treatment for at least 1 year, rhIGF-1 significantly increased height velocity, defined ...